KR20180058110A - Composition for coatimng of implant comprising marine algal sulphated polysaccharides-capsosiphon fulvescens - Google Patents

Abstract

The present invention relates to a composition for coating an implant comprising marine algae-derived sulfated polysaccharide-Capsosiphon fulvescens (SPS-CF) as an effective component. The SPS-CF can be easily demanded and supplied, and has an excellent osteolysis-inhibiting effect on osteoclasts, so that the bone formation in the periphery of the implant applied with the composition is greatly increased.

Description

TECHNICAL FIELD [0001] The present invention relates to an implant coating composition containing seaweed-derived SPS-CF as an effective ingredient. BACKGROUND ART < RTI ID = 0.0 >

The present invention relates to an implant coating composition comprising a saccharide -derived polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) as an active ingredient.

Recently, low birth rate and average life expectancy increase the domestic society into the age of aging, and the demand for the elderly welfare and health care is also increasing. Particularly, as the aging process progresses, there is a growing interest in the treatment of geriatric diseases. According to the Health Insurance Statistical Yearbook of 2014, the elderly who are 65 years old or older have the highest number of outpatient multiple illnesses treated by medical institutions, the highest in essential hypertension is 2.357 million, the second is gingivitis and periodontal disease is 1.85 million It records. In 2014, the Ministry of Health and Welfare announced that it would support implant treatment costs for recipients of medical benefits of 75 years or older. In 2015, it will be over 70 years old, 2016 In the year, the target range of 65 years or older was expanded to increase the demand for expensive implant treatment by strengthening medical care.

On the other hand, implant treatment is becoming popular not only for the elderly but also for the young people under 65 years old due to the changed eating habits and the reason of the cosmetic reasons. Korea is ranked as the top one in the annual distribution of dental implants in the world, Is expected to expand gradually (Straumann Annual Report, 2012).

Dental implants are performed in functional and aesthetic terms, and each implant that is inserted into the gum bone is called an implant. At present, the use of titanium, which is biocompatible and harmless to the human body, is used as an implant material, but the number of side effects of implants was the highest among dental disputes (Korea Consumer Agency, 2014) Side effects such as dislocation and breakage were observed in more than half of the patients. The causes of side effects were age of the patient, proficiency of the operator, management after the operation, and quality of the implants. Recently, the field of implant has been focused on inducing early osseointegration after implant placement in order to shorten the treatment period while minimizing the side effects of such implants.

Osteosynthesis in implants means direct contact between living cells and implants. Existing titanium implants have been found to form an oxide layer on the surface, preventing direct contact between bone and metal, and preventing metal corrosion and toxic reactions to cells surrounding the implant. However, the direct contact between the titanium and the gum bone is only 50 to 60% of the osseointegration, and various implant surface treatments have been attempted according to reports that the degree of successful osseointegration of the implant is determined by the surface treatment. In order to solve the side effects of titanium implants, it is necessary to develop effective coating agents for osseointegration. The conditions that the implant coating must have for osseointegration should have features such as biocompatibility, implant shape, contact surface with cells, bone condition at the surgical site, surgical procedure, and loading conditions. At this time, the coating on the contact surface with cells has been focused on the biocompatibility of the implants, and efforts are being made to find a new implant coating material.

Currently, many implant manufacturers are researching physiologically active substances related to surface treatment of implants. They are proteins or peptides, among which bone-forming proteins (BMP-2) are most actively developed. Recently, it has been reported that Megagen Implant has succeeded in developing BMP-2 coated implants. In addition, research on the development of implants coated with bone cell growth factors and osteoclast inhibitors Implants with coatings are under study. (Ministry of Commerce, Industry and Energy, 2014).

Polysaccharide polymers are rapidly emerging as high value-added biomaterials by combining their hydrophilic and biocompatible characteristics in various fields. Especially, highly stable plant polysaccharides are natural polymers and have already been applied in the fields of pharmaceuticals, cosmetics, foods and the like. Among these polysaccharides, polysaccharide polymers derived from seaweeds are attracting attention as a next-generation natural living resource, and their functional bioactivity has recently been discovered, and the application field is expected to expand further. In particular, in relation to bone formation, fucoidan has been reported to promote bone formation by increasing BMP-2 production in bone cells (Kim, 2009; Kim, 2015), and heparin, a sulfate polysaccharide, also promotes bone- (Takada et al., 2003). However, there is no research on the characterization of the polysaccharide polymers extracted from the seaweed, which is one of the major consuming algae in Korea, and the development of the osteoporosis improvement effect and further development of the implant coating material using the same.

The present invention is to provide an implant coating composition comprising a saccharide -derived polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) as an active ingredient.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

The present invention provides an implant coating composition comprising as an active ingredient polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) derived from mesophilia .

The composition may be one having osteoclastic bone resorption inhibitory ability.

The composition may be one that reduces protein expression of TRAF6, P-Src, Gelsolin or Carbonic anhydrase II.

The composition may be to reduce the formation of actin rings in osteoclasts.

The composition may have a viscosity of from 75 cP to 95 cP at 25 < 0 > C.

The composition may have a viscosity of from 70 cP to 100 cP at a pH of 7.

The composition may have a viscosity of from 50 cP to 90 cP at a pH of 8.

The composition may have a viscosity of from 50 cP to 100 cP at a concentration of 1.0%.

The content of the polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) contained in the composition may be 1 to 3% by weight of the total weight of the composition.

The composition for implant coating according to the present invention contains SPS-CF extracted from a marine algae which is one of major consuming seaweeds in Korea as an effective ingredient. It is easy to supply and receive the SPS-CF and has excellent osteoclast inhibitory effect on osteoclasts Therefore, it is effective to provide a composition for implant coating excellent in biocompatibility and biocompatibility.

1 is a schematic view showing a process of extracting and purifying a polymer polysaccharide polymer from a mesophyll.
Figure 2 shows the chemical composition of the polysaccharide polymer (SPS-CF).
Figure 3 shows the analysis of the polysaccharide polymer (SPS-CF) by HPLC.
Fig. 4 shows the molecular weight measurement results of the polysaccharide polymer (SPS-CF) by HPLC.
Figure 5 shows the results of cytotoxicity of polysaccharide polymer (SPS-CF) on macrophages and osteoclasts.
FIG. 6 shows TRAP (+) staining and activity measurement of osteoclast bone resorption inhibition of polysaccharide polymer (SPS-CF).
FIG. 7 shows the results of measurement of the inhibitory effect of polysaccharide polymer (SPS-CF) on osteoclast inhibition of Actin ring formation.
FIG. 8 shows the results of inhibiting the expression of osteoclast bone resorption proteins TRAF 6, P-Src, Gelsolin and Carbonic anhydrase by treatment with a polysaccharide polymer (SPS-CF).
9 shows the measurement results of viscosity change of polysaccharide polymer (SPS-CF) by concentration.
10 shows the measurement results of the viscosity change of the polysaccharide polymer (SPS-CF) according to the salt (NaCl) and the pH concentration.
Fig. 11 shows the measurement results of viscosity change of polysaccharide polymer (SPS-CF) by temperature.
Fig. 12 shows the measurement results of emulsification activity and emulsion stability of the saccharide polymer (SPS-CF).
Fig. 13 is a SEM image of the result of coating the surface of an implant on a polysaccharide polymer (SPS-CF), wherein (a) shows an SEM photograph of the implant without treatment of the polysaccharide polymer (SPS-CF) (3,000 times magnification) and (b) SEM photographs (1,000 times and 3,000 times magnification from the right) of implants treated with polysaccharide polymer (SPS-CF).

The present inventors have made efforts to overcome the problems such as improvement of quality such as the speed of bone bond after implantation of the conventional implant coating agent and found that polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens and the possibility of an implant coating agent, thereby completing the present invention.

The term "composition for implant coating" in the present specification refers to polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) as an active ingredient, and has excellent anti-osteoporotic effect against osteoclasts. Therefore, the implant coated with the composition of the present invention has an advantage that the bone formation of the periphery where the implant is implanted is greatly increased.

Hereinafter, the present invention will be described in detail.

The present invention provides an implant coating composition comprising as an active ingredient polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) derived from mesophilia .

Specifically, the polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) derived from the above-mentioned saccharide is a high molecular polysaccharide having a molecular weight of about 385 kDa and is a natural macromolecule material which does not show cytotoxicity in macrophages. Also, the SPS-CF contains rhamnose, xylose and mannose as main components.

Furthermore, in the implant coating composition according to the present invention, the polysaccharide SPS-CF derived from the mesenchyme is separated and purified by anion exchange column chromatography after extracting the acid from the mesophyll and precipitating the water-soluble extract obtained by ethanol precipitation, Ethanol, methanol, butanol, diethyl ether, ethyl acetate, and dimethylsulfoxide in water at a ratio of 1: 1 to 1: 1 with water, followed by an ethanol precipitation method after hot water extraction as commonly used in the art and a polar volatile solvent such as ethanol, To 1: 5, and more preferably, it is obtained by a 75% ethanol precipitation method. However, the present invention is not limited thereto.

The composition may be characterized by having osteoclastic bone resorption inhibitory ability.

Specifically, as shown in FIG. 6, it can be seen that the TRAP activity decreases depending on the concentration of SPS-CF. When the concentration of SPS-CF is 50 μg / ml, the decrease is more than 50% .

The composition may be characterized by decreasing protein expression of TRF6 (TNF receptor associated factor 6), P-Src (Phospho-Src), Gelsolin or Carbonic anhydrase II. Specifically, as shown in FIG. 8, it was confirmed that the expression of TRAF6, P-Src, Gelsolin, or Carbonic anhydrase II, an osteoclast bone resorption protein, was inhibited in a concentration-dependent manner by SPS-CF.

In addition, the composition may be characterized by reducing the formation of actin rings in osteoclasts.

After osteoclasts undergo differentiation, they undergo cytoskeletonization, which is a specific phenomenon that appears only in osteoclasts. To distinguish osteoclasts from osteocytes and spaces that absorb bone and osteoclasts, osteoclasts Of actin are organized into one large ring. That is, in osteoclasts, the formation of the actin ring is an important marker of the ability of cells to absorb bone.

Specifically, as shown in FIG. 7, it can be confirmed that SPS-CF decreases the size of the actin ring and the number of osteoclasts in a concentration-dependent manner.

Further, the composition may be characterized by having a viscosity of from 75 cP to 95 cP at 25 캜.

The composition may be characterized by having a viscosity of from 70 cP to 100 cP at pH 7 and a viscosity of from 50 cP to 90 cP at pH 8.

The composition may be characterized by having a viscosity of 50 cP to 100 cP at a concentration of 1.0%.

That is, SPS-CF according to the present invention has physical stability and stability against viscosity and temperature, and can be utilized as a composition for implant coating.

The implant coating composition according to the present invention comprises the polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens may be 1 to 3% by weight, preferably 1 to 2% by weight, based on the total weight of the composition, but is not limited thereto.

At this time, when the content of SPS-CF is less than the above range, there is a problem that the bone formation of the peripheral part in which the implant is implanted is insufficient in increasing the effect.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[ Example ]

EXAMPLES Example 1. Extraction of Polysaccharide Polymers Derived from Saccharomyces

Capsosiphon from Wando, Jeollanam-do fulvescens 13.09 g (dry weight) was immersed in 1 L of 0.01N hydrochloric acid (HCl) solution and acid hydrolyzed at room temperature for 24 hours. The hydrolyzed extract was filtered using female stockings and neutralized with 1N sodium hydroxide (NaOH).

Thereafter, ethanol was added to make a 75% ethanol solution, which was then precipitated at 4 ° C for 24 hours and centrifuged at 6000 rpm for 30 minutes at 4 ° C to obtain a precipitate. The precipitate was dissolved again in distilled water, and the solution was titrated to pH 2.0 with 1N hydrochloric acid, and then treated to a final concentration of 2M of calcium chloride (CaCl ₂ ) and stirred for 2 hours. The supernatant was centrifuged at 6000 rpm for 30 minutes at 4 째 C, and the supernatant was collected. The supernatant was treated with ethanol to make a 75% ethanol solution and precipitated at 4 째 C for 24 hours. The precipitate was obtained by centrifugation at 6000 rpm for 30 minutes at 4 째 C, followed by dissolution in 50 mL of distilled water, and dialysis was performed using a dialysis membrane having MWCO (cut-off molecular weight) of 14,000. The dialyzed samples were lyophilized to obtain 0.8336 mg of the crude polysaccharide, and the crude polysaccharide had a yield of 6.37%.

Then, the crude polysaccharide was dissolved in distilled water at 50 mg / 10 mL and separated by DEAE-cellulose column chromatography (3 x 22 cm). The resulting fractions were detected with phenol sulfuric acid and the sugar-detected fractions were collected Dialyzed with a dialysis membrane of MWCO (fraction molecular weight) of 14,000 and lyophilized. As a result, 19.035 mg of SPS-CF was obtained, and the SPS-CF showed a yield of about 2.42% (Fig. 1).

Example 2. Chemical composition analysis of polysaccharide polymer (SPS-CF)

In order to quantitatively analyze the chemical components of the polysaccharide polymer (SPS-CF), total sugar, sulfate group, uronic acid and protein were quantified (FIG. 2).

2-1. Total amount of polysaccharide polymer (SPS-CF)

Total sugar content was determined by phenol-sulfuric acid method using glucose as a standard solution. 20 L of a 5% phenol solution was added to 200 L of the sample solution. Then, 2 μL of sulfuric acid solution was added, and the mixture was stirred at room temperature for 20 minutes. This was measured at 490 nm using an ELIZA reader.

2-2. Determination of sulfate group of polysaccharide polymer (SPS-CF)

The amount of sulfuric acid was determined by the Bitter method using sulfuric acid as a standard solution. 5 μL of a polysaccharide polymer (SPS-CF) prepared at 1 mg / mL and 10 mg / mL, respectively, was added with 5 μL of 0.02 N NaOH and heated with an alcohol lamp for about 10 minutes. In a completely dried test tube, 0.24 mL of distilled water was added, and 0.1 mL of the solution was divided into 15 mL conical tubes. 5 mL of 2N acetic acid, 1 mL of 0.01 M BaCl ₂ , and 4 mL of 0.02 M NaHCO ₃ were added. 0.6 mL of barium buffer filled up and mixed.

Then, add 5 mL of Rhodizonate and 100 mg of ascorbic acid in 20 mL of distilled water, add 80 mL of ethanol, add 0.3 mL of the prepared Rhodizonate reagent, and mix well. The solution was reacted at room temperature for 10 minutes and then measured at 520 nm using a spectrophotometer.

2-3. Quantitative determination of uronic acid in polysaccharide polymer (SPS-CF)

Quantitative determination of uronic acid was performed using the Loui method using D-galacturonic acid as a standard solution. Add 0.9 g of sodium tetraborate decahydrate to 10 mL of distilled water maintained at 4 ° C in 250 μL of a 1% polysaccharide polymer (SPS-CF) maintained at 4 ° C, add 1.5 mL of a solution containing 90 mL of 98% sulfuric acid maintained at 4 ° C And heated at 100 占 폚 for 10 minutes.

Then, 50 μL of a solution in which 100 mg of cabazole was dissolved in 100 mL of ethanol was added by heating the solution at 100 ° C. for 15 minutes. After cooling the solution, the absorbance was measured at 525 nm.

2-4. Protein quantification of polysaccharide polymer (SPS-CF)

Protein quantification was performed by the Bradford method using bovine serum albumin (BSA) as a standard solution. Polysaccharide polymer (SPS-CF) was prepared at 1 mg / mL.

Then, 10 μL of the polysaccharide polymer was collected, placed in a 96-well plate, and 200 μL of Bradford reagent was added thereto and mixed.

Thereafter, ELISA reader was used at 595 nm.

Example 3. Neutral sugar qualitative and quantitative analysis of polysaccharide polymer (SPS-CF)

In order to qualitatively and qualitatively analyze the polysaccharide polymer (SPS-CF), 1% solution was dissolved in distilled water and acid hydrolyzed with 2M TFA (trifluoroacetic acid) at 100 ℃ for 4 hours. And the sample was dried.

The dried sample was dissolved in HPLC water at a concentration of 1% and filtered through a 0.22 μm Spin-X tube.

Afterwards, HPAEC-PAD (high-pH anion exchange chromatography with pulsed amerometric detection) was performed using Bio-LC (LC 20 Chromatography Enclosure, Dionex, Co., USA). Fucose, rhamnose, arabinose, galactose, glucose, mannose and xylose purchased from Sigma (USA) were used as the standard neutral sugars. The column was eluted with CarboPac PA-1 (4 x 250 mm, Dionex, Thermo Scientific, USA) and the concentration was adjusted to 0.7 mL / min with distilled water and 200 mM NaOH. Qualitative analysis was performed by comparing the retention time (min) values of each peak. The quantification was performed by comparing the peak areas using Chormeleon software (Thermo Scientific, USA).

As a result of the neutral sugar analysis, polysaccharide polymer (SPS-CF) was identified as a sugar mainly composed of xylose, rhamnose and mannose, and their mole ratios were found to be 4.24, 2.04, and 10.42 mole%, respectively ).

Example 4. Molecular weight measurement of polysaccharide polymer (SPS-CF)

Size-exclusion HPLC (Waters Alliance HPLC 2695, USA) was used to measure the relative molecular weight of polysaccharide polymer (SPS-CF). The column used was a Shodex OHpack column (SB-showdex 806HQ), and the sample was filtered with 0.22 μm Spin-X to 1% of the prepared polysaccharide in HPLC water. 10 μL of the sample was injected into the column, and the flow rate was detected at 0.7 mL / min. Pullulan and Blue dextran were used as relative molecular weight standards.

As a result, it was confirmed that the polysaccharide polymer (SPS-CF) was a high molecular polysaccharide of about 385 kDa (FIG. 4).

Example 5. Analysis of anti-osteoporosis effect of polysaccharide polymer (SPS-CF)

The anti-osteoporotic effect of the polysaccharide-derived polysaccharide polymer extracted in Example 1 was analyzed.

5-1. Cytotoxicity of polysaccharide polymer (SPS-CF)

Cell viability was measured by MTT assay to determine the cytotoxicity of RAW264.7 and osteoclasts in polysaccharide polymer (SPS-CF).

RAW264.7 cells were treated with 50ng / ml of RANKL to differentiate into osteoclasts and treated with sporulated polysaccharides (SPS-CF) at different concentrations (0, 10, 30, 50 ㎍ / ㎖) As a control, cytotoxicity of RAW 264.7 cells before osteoclast differentiation was also examined by treating the same polysaccharide at the same concentration (Fig. 5).

5-2. Effect of polysaccharide polymer (SPS-CF) on osteoclast differentiation inhibition

To investigate the ability of polysaccharide polymer (SPS-CF) to inhibit osteoclast bone resorption, TRAP (+) activity measurement and TRAP (+) staining were performed to measure osteoclast bone resorption of RAW264.7 cells.

TRAP staining is a staining method for measuring osteoclast bone resorption scale. TRAP (tartrate-resistant acid phosphatase) is a bone resorption marker specifically made in osteoclast. It is an acidic lysosomal enzyme and plays a role similar to alkaline phosphatase in an acidic environment It refers to various proteins to be performed.

The degree of osteoclast differentiation was measured by TRAP staining reagent after treating polysaccharide polymer (SPS-CF) at different concentrations (0, 10, 30, 50 ㎍ / ㎖) while differentiating RAW264.7 osteoclasts 100% (Fig. 6).

5-3. Suppression of osteoclast differentiation protein expression of polysaccharide polymer (SPS-CF)

To investigate the changes of protein expressed by polysaccharide polymer (SPS-CF) during osteoclast differentiation, polysaccharide polymer (SPS-CF) was added to RAW264.7 osteoclasts at concentrations of 0, 10, 30 and 50 μg / ) And RAW264.7 cells not treated with differentiation (control group).

The expression of TRAF6, P-Src, Gelsolin and Carbonic anhydrase II proteins, known as markers of osteoclast differentiation, was determined by Western blot analysis. Also, actin ring staining revealed a decrease in the size of the Actin ring and a decrease in the number of osteoclasts. Actin ring staining was stained with Rhodamin phalloidin and observed by fluorescence microscopy (FIGS. 7 and 8).

As a result, it was confirmed that the polysaccharide polymer (SPS-CF) induces the expression of TRAF6, P-Src, Gelsolin and Carbonic anhydrase II protein in a concentration-dependent manner.

Example 6. Viscosity analysis of polysaccharide polymer (SPS-CF)

6-1. Viscosity change by concentration of polysaccharide polymer (SPS-CF) in 0.1M NaCl

The polysaccharide polymer (SPS-CF) isolated in Example 1 was dissolved in a 0.1M NaCl solution at a constant concentration (0.1, 0.25, 0.5, 0.75, 1%) and then measured with a rotational viscometer (Broocfield LVDVI + ) Was used to measure the viscosity at 25.00 ± 0.02 ° C (FIG. 9 (a)).

As a result, it was confirmed that as the concentration of the polysaccharide polymer (SPS-CF) increases, the viscosity decreases.

6-2. Viscosity change by concentration

The polysaccharide polymer (SPS-CF) isolated in Example 1 was dissolved in distilled water in concentrations of 0.1, 0.25, 0.5, 0.75 and 1%, and then a rotational viscometer (Broocfield LVDVI +, Brookfield Engineering Ltd., USA) And the viscosity change at each concentration was measured at 25 캜 (Fig. 9 (b)).

As a result, it was confirmed that as the concentration of the polysaccharide polymer (SPS-CF) increases, the viscosity decreases.

6-3. Viscosity change by salt concentration

The polysaccharide polymer (SPS-CF) isolated in Example 1 was dissolved in distilled water at a concentration of 1%, and the NaCl solution was mixed at concentrations of 0.25, 0.5, 1.0, 2.0 and 5.0% Brookfield Engineering Ltd., USA) or the like (Fig. 10 (a)).

As a result, it was confirmed that when the concentration of NaCl was 0.5M, the polysaccharide polymer (SPS-CF) had the highest viscosity of about 18 cP.

6-4. Viscosity change by pH

The polysaccharide polymer (SPS-CF) isolated in Example 1 was dissolved in distilled water at a concentration of 1%, and the solution was mixed with pH values (pH 2 to pH 11) (Fig. 10 (b)).

As a result, it was confirmed that the viscosity of the polysaccharide polymer (SPS-CF) was remarkably high at pH 7 and 8.

6-5. Viscosity change by heat treatment

The polysaccharide polymer (SPS-CF) isolated in Example 1 was dissolved in distilled water at a concentration of 1% and then heat-treated at 40 ° C, 60 ° C, 80 ° C, 100 ° C for 30 minutes, cooled at 25 ° C for 15 minutes, Broocfield LVDVI +, Brookfield Engineering Ltd., USA) was used to measure the viscosity change by heat treatment (FIG. 11).

As a result, it was confirmed that the viscosity was 90 cP or more in the temperature range of 25 ° C to 80 ° C. That is, the polysaccharide polymer (SPS-CF) according to the present invention is stable to temperature change.

Example 7. Analysis of Emulsifying Activity and Emulsion Stability of Polysaccharide Polymer (SPS-CF)

7-1. Emulsion activity analysis

2 mL of the measurement solution was mixed with 2 mL of 0.2 M phosphate buffer buffer, pH 7, 1 mL of each substrate was added, and emulsified by stirring for 1 minute. Thereafter, the suspension was allowed to stand for 10 minutes, and the degree of suspension at 540 nm was measured using a spectrophotometer (Fig. 12 (a)).

7-2. Emulsion stability analysis

The measurement solution was emulsified in the same manner as in Example 7-1.

Thereafter, the suspension was measured at 540 nm for 60 minutes every 10 minutes while being left at room temperature, and converted into Log value (Fig. 12 (b)).

As a result, it was confirmed that the silicone oil has a relatively higher emulsifying activity than the other solvents, while the emulsion stability is lower.

Example 8. Analysis of implant coating and surface treatment ability of polysaccharide polymer (SPS-CF)

Implant coating of polysaccharide polymer (SPS-CF) was applied to 100 mL of 1% SPS-CF using Dipping & Drying method.

After immersing in 1% SPS-CF solution for 1 hour, the implant was coated and dried at 65 ° C for 30 minutes to induce fixation of the material.

Then, the surface treatment ability analysis was performed at 30 times, 1,000 times, 3,000 times, and 20,000 times with a scanning electron microscope (HITACHI, Japan) to confirm the coating of the polysaccharide polymer.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

Claims (9)

Wherein the polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) is used as an active ingredient.
The method according to claim 1,
Wherein said composition has the ability to inhibit bone resorption of osteoclasts
Implant coating composition.
The method according to claim 1,
The composition is characterized in that it reduces protein expression of TRF6 (TNF receptor associated factor 6), P-Src (Phospho-Src), Gelsolin or Carbonic anhydrase II
Implant coating composition.
The method according to claim 1,
Wherein said composition reduces the formation of actin rings in osteoclasts
Implant coating composition.
The method according to claim 1,
Characterized in that the composition has a viscosity at 25 DEG C of from 75 cP to 95 cP
Implant coating composition.
The method according to claim 1,
Characterized in that the composition has a viscosity of from 70 cP to 100 cP at pH 7
Implant coating composition.
The method according to claim 1,
Characterized in that the composition has a viscosity of from 50 cP to 90 cP at a pH of 8
Implant coating composition.
The method according to claim 1,
Characterized in that the composition has a viscosity of from 50 cP to 100 cP at a concentration of 1.0%
Implant coating composition.
The method according to claim 1,
The content of the polysaccharide SPS-CF (sulphated polysaccharides- Capsosiphon fulvescens ) contained in the composition is 1 to 3% by weight of the total weight of the composition
Implant coating composition.

Images